Articles
Page 7 of 19
-
Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P221
-
HIV testing in non-traditional settings: feasibility and acceptability in an acute admissions unit
Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P219 -
Trends in human papillomavirus (HPV) infection among HIV-positive women in the pre-HAART and HAART era in a Nigerian clinic
Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P217 -
Detrimental clinical interaction between ritonavir-boosted protease inhibitors and vinblastin in HIV-infected patients with Hodgkin lymphoma
Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P215 -
Relationship between dynamics of Epstein-Barr virus and immune activation in HIV-1 infected subjects in the HAART era
Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P213 -
Response to treatment of hepatitis C in HCV/HIV co-infected patients is not influenced by either abacavir or tenofovir with weight-based ribavirin
Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P211 -
Efficacy and safety of therapy of chronic hepatitis B with telbivudine (LdT) in patients with HIV-infection without HAART
Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P209 -
Effectiveness of pegylated interferon alfa plus HAART in HIV/HBV treatment-naïve coinfected patients
Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P207 -
Pharmacokinetic (PK) and pharmacodynamic analyses of once- and twice-daily darunavir/ritonavir (DRV/r) in the ODIN trial
Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P185 -
Impact of CYP2B6 and CYP2A6 polymorphisms on efavirenz plasma concentrations in Ghanaian HIV-infected patients
Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P183 -
Population pharmacokinetic and pharmacogenetic analysis of nevirapine in hypersensitive and tolerant HIV-infected patients from Malawi
Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P181 -
A filter-based cross-sectional analysis of an HIV-positive, HAART-treated cohort in rural Burundi: pharmacokinetics, pharmacogenetics and viral load
Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P179 -
Therapeutic drug monitoring (TDM) of atazanavir in pregnancy
Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P177 -
T-CD4+ cell count at the date of the HIV diagnosis
Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P175 -
What drives a normal relation between T-CD4 and T-CD8?
Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P152 -
Lack of utility of phosphate serum monitoring in HIV-infected patients on a tenofovir-based antiretroviral regimen
Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P150 -
Effect of lipemia and bilirubinemia on HIV-1 protease and reverse transcriptase genotyping and phenotyping success: a five-year analysis
Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P148 -
High prevalence of the UGT1A1*28 variant in HIV-infected individuals in Greece
Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P146 -
Haemoglobin and anaemia in the SMART study
Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P144 -
Development of drug resistance among HIV-1 F1 sub-type patients with treatment failure
Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P142 -
HIV drug resistance in children with treatment failure to first-line regimens in Ho Chi Minh City, Vietnam
Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P140 -
Is extended resistance to the historical antiretroviral drugs & drug classes still a risk factor for HIV progression?
Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P138 -
Assessing the risk of birth defects associated with atazanavir exposure in pregnancy
Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P113 -
Muscle symptoms and creatine phosphokinase elevations in patients receiving raltegravir in clinical practice: results from a multicenter study
Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P111 -
Sexual dysfunction and anxiety in HIV-1-infected males in Eastern Sicily
Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P109 -
Continuing burden of HIV late presenters in the North East of England 2009
Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P107 -
Prevalence and factors associated with severe vitamin D deficiency in HIV/hepatitis C co-infected patients
Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P103 -
Clinical significance of hyperbilirubinemia in the CASTLE study
Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P93 -
Liver safety of two nucleoside analogs plus efavirenz, nevirapine or a ritonavir-boosted protease inhibitor in HIV/HCV-coinfected drug-naïve patients
Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P91 -
Prevalence of chronic renal failure stage 3 or more in HIV-infected patients in Antwerp: an observational study
Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P89 -
Intracellular tenofovir-diphosphate accumulation in an HIV-infected patient with Fanconi syndrome and osteomalacia
Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P87 -
Kidney tubular function and serum phosphate levels in HIV-1-infected patients treated with tenofovir: preliminary results
Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P83 -
Treatment of HIV-2 infection: a retrospective study from a Portuguese center
Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P54 -
Changes in cerebral function parameters in HIV-1 infected subjects undergoing a treatment simplification to darunavir/ritonavir
Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P52 -
Lopinavir/ritonavir monotherapy in clinical practice
Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P50 -
Analysis of determinants of long-term efficacy of unboosted atazanavir-based regimens in the clinical setting
Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P48 -
HIV entry blocked by maraviroc can cause an overestimation of viral load
Citation: Journal of the International AIDS Society 2010 13(Suppl 4):O46 -
Lopinavir to atazanavir or darunavir switch in HIV-1-infected patients with dyslipidemia: an observational study
Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P46 -
Vitamin D and HIV: shine a light
Citation: Journal of the International AIDS Society 2010 13(Suppl 4):O42 -
Highlights of the 12th International Workshop on Adverse Drug Reactions and Co-Morbidities in HIV, London, November 2010
Citation: Journal of the International AIDS Society 2010 13(Suppl 4):O38 -
Adolescents with perinatally acquired HIV — coming your way
Citation: Journal of the International AIDS Society 2010 13(Suppl 4):O36 -
Response to HAART according to sex and origin (immigrant vs autochthonous) in a cohort of patients who initiate antiretroviral treatment
Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P21 -
Efficient immune reconstitution in HIV+ naïve patients (pts) starting a first lopinavir/ritonavir-containing regimen with low CD4 counts
Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P17 -
Factors associated with treatment modification during the first year of contemporary HAART
Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P15 -
Reasons for treatment discontinuation in the first year after beginning antiretroviral therapy in a cohort of Portuguese HIV-infected patients
Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P13 -
O125. Influence of amount and percentage of CXCR4-using virus in predicting week 48 responses to maraviroc in treatment-naïve patients
Citation: Journal of the International AIDS Society 2010 13(Suppl 4):O11 -
Comparative efficacy and safety of regimens including ritonavir-boosted lopinavir or nevirapine in antiretroviral-naïve HIV-1-infected individuals
Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P11 -
Outcomes in antiretroviral-naive HIV-infected patients initiating therapy with TDF/FTC plus either atazanavir/r or another third recommended drug
Citation: Journal of the International AIDS Society 2010 13(Suppl 4):P9 -
ART achievements and challenges in Africa
Citation: Journal of the International AIDS Society 2010 13(Suppl 4):K3 -
Why suppression of HIV replication does not always make everything better
Citation: Journal of the International AIDS Society 2010 13(Suppl 4):K1